Kevin Conroy, Chairman and CEO of Exact Sciences, shared a post on LinkedIn:
“This year, the Exact Sciences team accomplished something extraordinary: we successfully launched three new tests that transform the way cancer is detected and managed. With the introduction of Cancerguard (our multi-cancer early detection test), Cologuard Plus (the next generation of our trusted colorectal cancer screening test), and Oncodetect (our molecular residual disease test), we expanded our portfolio in powerful ways that directly benefit patients.
Bringing even one new test to market requires years of science, innovation, and dedication. Launching three in a single year is a remarkable feat and a testament to our team’s expertise and passion. These new tests provide more answers to patients and move us closer to our mission of eradicating cancer through early detection and smarter answers.”
More posts featuring Kevin Conroy.